Welcome to our dedicated page for Passage Bio news (Ticker: PASG), a resource for investors and traders seeking the latest updates and insights on Passage Bio stock.
Passage Bio, Inc. (NASDAQ: PASG) is a clinical stage genetic medicines company whose news flow centers on the development of its lead gene therapy candidate, PBFT02, for neurodegenerative diseases. Company updates frequently highlight progress in the Phase 1/2 upliFT-D trial in frontotemporal dementia with GRN or C9orf72 mutations, including cohort enrollment, dosing milestones, and interim biomarker and safety data.
Investors following PASG news can expect regular announcements of quarterly and annual financial results, where Passage Bio reports research and development spending, general and administrative expenses, net loss, and cash, cash equivalents, and marketable securities, along with commentary on expected cash runway. These releases often include recent business highlights related to PBFT02, such as data readouts on cerebrospinal fluid progranulin levels, plasma neurofilament light chain trends, and protocol amendments intended to refine the benefit–risk profile of the program.
News items also cover regulatory and manufacturing developments, including interactions with the U.S. Food and Drug Administration on analytical comparability for a high-productivity, suspension-based PBFT02 manufacturing process, and plans to seek feedback on potential registrational trial designs. In addition, Passage Bio regularly announces participation in healthcare, genetic medicines, and biopharma investor conferences, where management presents corporate overviews and program updates.
This page aggregates these disclosures, offering a centralized view of Passage Bio’s clinical, regulatory, financial, and corporate communications. Readers interested in PASG can use this news feed to track the evolution of the PBFT02 program, changes in trial design, manufacturing strategy, and key financial and listing-related events such as the company’s reverse stock split and subsequent confirmation of compliance with Nasdaq listing requirements.
Passage Bio (Nasdaq: PASG) announced FDA clearance for its IND application for PBML04, a gene therapy targeting Metachromatic Leukodystrophy (MLD), a rare and fatal pediatric condition. This marks the company’s fourth IND clearance and the third pediatric lysosomal storage disorder to enter clinical development. MLD affects 1 in 100,000 live births and is caused by mutations in the ARSA gene. The Phase 1 trial will utilize ICM administration of an AAVhu68 capsid to express ARSA, offering potential treatment for MLD's severe symptoms.
Passage Bio (Nasdaq: PASG) announced the departure of Bruce Goldsmith, Ph.D., as president and CEO, effective immediately, with Edgar B. (Chip) Cale stepping in as interim CEO. Cale, the current general counsel, will lead the company while a search for a permanent CEO is underway. Over the past two years, Goldsmith oversaw significant achievements, including successful public offerings and advancing three clinical development programs. The board expressed gratitude for his contributions, emphasizing continuity in leadership during this transition.
Passage Bio, a clinical-stage genetic medicines company, has granted inducement awards to new employees, consisting of options to purchase 79,600 shares of common stock at an exercise price of $1.69 per share. This price reflects the stock's closing value on May 16, 2022. The options will vest over four years, with 25% vesting after one year. Passage Bio's focus is on developing therapies for central nervous system disorders, with ongoing clinical programs in GM1 gangliosidosis, Krabbe disease, and frontotemporal dementia.
Passage Bio (NASDAQ: PASG) announced positive interim results from the Imagine-1 Phase 1/2 trial of PBGM01, a gene therapy for GM1 gangliosidosis. Data presented showed that PBGM01 was well-tolerated and exhibited a favorable safety profile without serious adverse events. Both patients in Cohort 1 demonstrated significant developmental improvements, particularly in motor and language skills. MRI results indicated increased brain volume in patient 1, while biomarker data confirmed functional gene expression. The trial continues with additional cohorts, and interim data from Cohorts 2 and 3 is expected in 2H22.
Passage Bio (NASDAQ: PASG) announced the dosing of its first patient in Cohort 2 and the completion of Cohort 3 in the Imagine-1 clinical trial for GM1 gangliosidosis. The GALax-C trial for infantile Krabbe disease has also initiated dosing. The company submitted an IND for PBML04 targeting metachromatic leukodystrophy and aims to extend its cash runway into Q2 2024 through strategic prioritization and a workforce reduction. Financial results for Q1 2022 reported a net loss of $42.8 million, with cash reserves of $267.1 million, sufficient to support ongoing operations into 2024.
Passage Bio (NASDAQ: PASG) will host a conference call on May 16, 2022, at 8:30 a.m. ET to discuss its first quarter 2022 financial results and recent business highlights. The call can be accessed by dialing 833-528-0605 (domestic) or 830-221-9711 (international) with conference ID 6960234. A live audio webcast will also be available on the company's investor website, with an archived version to follow. Passage Bio is focused on developing gene therapies for central nervous system disorders, with ongoing clinical programs targeting GM1 gangliosidosis, Krabbe disease, and frontotemporal dementia.
Passage Bio (NASDAQ: PASG) announced it will present additional clinical and biomarker data from the Imagine-1 study for GM1 gangliosidosis at the ASGCT 25th Annual Meeting on May 18, 2022, in Washington, D.C. The late-breaker oral presentation will feature interim safety, biomarker, and efficacy data for PBGM01, a therapy for both early and late-onset types of the disorder. Additionally, researchers from the University of Pennsylvania will present preclinical data supporting Passage Bio’s programs, including a study on PBML04 for metachromatic leukodystrophy.
Passage Bio (NASDAQ: PASG) announced that it will present additional clinical data from Cohort 1 of the Imagine-1 study for GM1 gangliosidosis at the ASGCT Annual Meeting from May 16-19, 2022, in Washington D.C. The late-breaker oral presentation will showcase interim safety and efficacy data, scheduled for May 18, 2022. Additionally, the University of Pennsylvania will present preclinical data supporting Passage Bio's Investigational New Drug application for Metachromatic leukodystrophy (MLD), also on May 18, 2022.
Passage Bio (Nasdaq: PASG) has granted inducement awards to new employees, issuing options to purchase 18,100 shares of common stock. The options feature an exercise price of $2.61 per share, corresponding to the shares' closing price on April 18, 2022. The vesting schedule includes 25% on the one-year anniversary and the remainder in monthly installments over three years. This move aligns with Nasdaq Listing Rule 5635(c)(4), emphasizing the company’s commitment to attracting top talent while focusing on developing transformative genetic therapies for central nervous system disorders.
Passage Bio (Nasdaq: PASG) has published significant preclinical results supporting the development of its gene therapy PBKR03 for infantile Krabbe disease, a severe pediatric condition. The studies, in collaboration with the University of Pennsylvania, demonstrated marked safety improvements and positive effects on disease progression in animal models, with no dose-limiting toxicities observed. Passage Bio is now enrolling patients for the GALax-C clinical trial, aiming to evaluate the potential of PBKR03 to effectively treat this rare disease.